The AEBP2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted population of HT29 colorectal adenocarcinoma cells, engineered to ablate the function of the transcriptional repressor AEBP2. This polyclonal knockout cell pool enables the study of AEBP2-dependent mechanisms within a heterogeneous genetic background, avoiding the clonal artifacts associated with single-cell-derived lines. The product provides a versatile loss-of-function model for dissecting Polycomb Repressive Complex 2 (PRC2) biology and its role in intestinal tumorigenesis.
The host HT29 cell line is derived from a human colorectal adenocarcinoma of a 44-year-old female, exhibiting an epithelial morphology and serving as a well-established model for mucin-secreting intestinal epithelium. HT29 cells are widely utilized to investigate colorectal cancer pathogenesis, including signal transduction, cell differentiation, and tumor stem cell maintenance. Their robust growth characteristics and responsiveness to epigenetic modulators make them an ideal platform for functional genomics applications targeting chromatin regulators.
AEBP2 is a zinc-finger accessory subunit of PRC2 that enhances the complex??s methyltransferase activity toward histone H3 lysine 27, generating the repressive H3K27me3 mark. It interacts directly with core PRC2 components EZH2, SUZ12, EED, and RBBP4, as well as the cofactor JARID2, to reinforce gene silencing. In colorectal cancer cells, AEBP2 functions downstream of oncogenic inputs such as ??-catenin/TCF, Notch1 intracellular domain, and MYC, transcriptionally repressing tumor suppressors and differentiation factors including CDKN2A, CDH1, the HOXA gene cluster, DKK1, and AXIN2. This repression involves interplay with PRC1 components BMI1 and RING1B, consolidating a chromatin state that maintains stemness and promotes tumor progression.
Disruption of AEBP2 in HT29 cells offers a physiologically relevant context to dissect how PRC2-mediated H3K27 methylation drives colorectal cancer phenotypes. The model allows researchers to evaluate the impact on epithelial gene regulatory networks, particularly those governing Wnt and Notch pathway outputs. By relieving AEBP2-dependent silencing, the knockout cells may exhibit derepression of key targets, enabling investigation of differentiation block release, altered proliferation, and sensitivity to small-molecule EZH2 inhibitors??interrogations that are central to understanding epigenetic vulnerabilities in tumors.
Researchers can employ this AEBP2 polyclonal knockout model in a broad array of experimental workflows. Western blotting and RT-qPCR can quantify changes in H3K27me3 levels and expression of AEBP2 target genes, while ChIP-qPCR maps H3K27me3 enrichment at loci such as CDKN2A or CDH1 promoters. Functional assays including MTT, colony formation, and invasion/migration tests probe tumorigenic capacity, complemented by RNA-seq for global transcriptomic profiling. Immunofluorescence reveals H3K27me3 foci dynamics, and co-immunoprecipitation validates PRC2 complex integrity. Drug sensitivity screens with EZH2 inhibitors (e.g., tazemetostat) allow assessment of synthetic vulnerabilities. For further information, please contact Ascent Research.
